Lilly Expands Legal Efforts Against Compounded Tirzepatide Sellers, Warns of Counterfeit Risks

1. Lilly Files Lawsuits: Eli Lilly has filed lawsuits against six sellers of compounded tirzepatide, alleging false advertising and deception of patients into believing they are selling FDA-approved products.
2. Counterfeit Risks: Lilly warns of the dangers of counterfeit and compounded versions of tirzepatide, which may contain incorrect dosages, bacteria, or other harmful substances.
3. FDA-Approved vs. Compounded: Compounded products are not FDA-approved and lack the same safety, quality, and efficacy protections as FDA-approved medicines.
4. Previous Legal Actions: Lilly had previously filed lawsuits against eight companies in September 2023 and has entered into settlements with some entities to stop misleading advertising practices.
5. Market Success: Lilly's tirzepatide products, Mounjaro and Zepbound, have reported combined sales of $5.4 billion and are projected to reach $34 billion by 2029.
6. Patient Safety: Lilly emphasizes that its GLP-1 products are indicated for serious diseases and should not be used for cosmetic weight loss or by people under 18.